contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


neola-medicals-ceo-highlights-recent-steps-toward-market-approval-in-the-autumn-2024-investor-letter

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Neola Medical is active in medical technology. The company is focused on neonatal care, where they develop medical equipment. Examples of products the company provides to healthcare include technical monitoring and follow-up of the lung capacity of premature babies. In addition to the main product, ancillary products and disposable items are offered. The largest activity is found within the Nordic market. The company previously went by the name GPX Medical.

Neola Medical

Neola Medical AB takes significant steps toward securing market approval in the USA for continuous lung monitoring device, Neola®. These accomplishments include the company’s transition from...

<div class="mfn-preamble"><p><strong>Neola Medical AB takes significant steps toward securing market approval in the USA for continuous lung monitoring device, Neola®. These accomplishments include the company’s transition from technical verification phase to clinical validation phase, preparing for clinical studies on preterm born babies. Building on the progress to clinical validation, recent patent grants in both the USA and Europe, are strengthening the company’s competitive position and reinforces the protection of its innovation pipeline of medical device for continuous lung monitoring.</strong></p></div><div class="mfn-body"><p>“We are making significant strategic advancements toward securing market approval in the USA for our continuous lung monitoring device, Neola®. We are not only advancing our commercialization strategy in the USA but also progressing to clinical validation, preparing a pivotal clinical study in the USA, which will be instrumental in supporting Neola Medical's forthcoming FDA application and bringing our medical device for continuous lung monitoring, Neola® to market.”, says CEO Hanna Sjöström.</p><p>Read more about the latest news in the investor letter autumn 2024, attached to this press release and available on the company’s website <a rel="noopener" href="http://www.neolamedical.com/">www.neolamedical.com</a></p></div><div class="mfn-footer mfn-contacts mfn-39c2feb1dc3d"><p><strong class="mfn-heading-1">For further information, contact:</strong><br>Hanna Sjöström, CEO<br>e-mail: <a rel="noopener" href="mailto:hanna.sjostrom@neolamedical.com">hanna.sjostrom@neolamedical.com</a></p></div><div class="mfn-footer mfn-about mfn-112561f0eca8"><p><strong class="mfn-heading-1">About Neola Medical</strong><br>Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/a1b2b8bc-b572-427a-870a-c9540836a486/neola-medicals-ceo-highlights-recent-steps-toward-market-approval-in-the-autumn-2024-investor-letter.pdf" class="mfn-generated mfn-primary">Neola Medical’s CEO highlights recent steps toward market approval in the Autumn 2024 Investor Letter</a><br><a rel="noopener" href="https://storage.mfn.se/534fd90a-a069-4ba2-9ed3-fad4a4627bad/neola-medical-investor-letter-autumn-2024.pdf">Neola Medical Investor Letter Autumn 2024</a></p></div>

Neola Medical’s CEO highlights recent steps toward market approval in the Autumn 2024 Investor Letter

Stay up to date with our newsletter